Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Acalabrutinib in Adults with Untreated Chronic Lymphocytic Leukemia
Sponsor: BeOne Medicines
ClinicalTrials ID:NCT07277231
This clinical trial is testing two different combinations of medications to see which is more effective and safe for adults with chronic lymphocytic leukemia (CLL) who have not received any previous treatment.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The aim of this study is to compare the effectiveness and safety of two medication combinations for treating chronic lymphocytic leukemia (CLL) in adults who have not been treated before. One group will receive sonrotoclax and zanubrutinib, while the other group will receive venetoclax and acalabrutinib. Researchers want to find out which combination works better and is safer for patients.
Eligibility Criteria
Inclusion Criteria
- Adults who have been diagnosed with chronic lymphocytic leukemia (CLL) and need treatment.
- Have not received any previous treatment for CLL.
- Have a performance status score of 0, 1, or 2, meaning fully active or with some restrictions in physical activity.
- Have measurable disease as shown by CT or MRI scans.
- Have good bone marrow and organ function.
Exclusion Criteria
- Have received any previous treatment for CLL.
- Have a type of leukemia called prolymphocytic leukemia or have had or are suspected to have a condition called Richter's transformation.
- Have cancer that has spread to the central nervous system.
- Have a history of a brain infection called progressive multifocal leukoencephalopathy (PML).
- Have uncontrolled high blood pressure or significant heart disease.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Fred Hutchinson Cancer Research Center | 98109-4433 | Seattle | Washington |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.